Management of an Allogeneic HSCT Recipient with an SICD During and After Total Body Irradiation.
1/5 보강
A 19-year-old woman with acute myeloid leukemia who had received a subcutaneous implantable cardioverter defibrillator (SICD) was scheduled to undergo allogeneic hematopoietic stem cell transplantatio
APA
Matsuoka A, Kimura SI, et al. (2026). Management of an Allogeneic HSCT Recipient with an SICD During and After Total Body Irradiation.. Internal medicine (Tokyo, Japan). https://doi.org/10.2169/internalmedicine.6197-25
MLA
Matsuoka A, et al.. "Management of an Allogeneic HSCT Recipient with an SICD During and After Total Body Irradiation.." Internal medicine (Tokyo, Japan), 2026.
PMID
41621864 ↗
Abstract 한글 요약
A 19-year-old woman with acute myeloid leukemia who had received a subcutaneous implantable cardioverter defibrillator (SICD) was scheduled to undergo allogeneic hematopoietic stem cell transplantation (HSCT). The conditioning regimen included total body irradiation (TBI) at a dose of 12 Gy, under which the SICD was considered at high risk for malfunction. We planned to deactivate and reactivate the SICD before and after each TBI session to mitigate the risk of device malfunction. Additionally, SICD shielding measures were implemented during TBI to minimize the risk of malfunction. Through these procedures, HSCT could be performed without significant adverse events linked to the SICD.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Augmented myeloablative conditioning with olaparib in allogeneic hematopoietic stem cell transplantation for relapsed/refractory RUNX1::RUNX1T1-positive acute myeloid leukemia.
- Short-course high-dose cytarabine consolidation therapy before allogeneic hematopoietic stem cell transplantation improves 2-year relapse-free survival but not overall survival in patients with acute myeloid leukemia: a single-center retrospective study.
- Total marrow irradiation-based conditioning for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A multicenter real-world study.
- Individualized decitabine dosing for post-HSCT maintenance in MDS and secondary AML from MDS: long-term outcomes from the PODAC trial and matched controls.
- Survival trends in young adults with acute leukaemia after AHSCT in Germany: comparisons with younger and older patients.
- Immune reconstruction after allogeneic hematopoietic stem cell transplantation: rules, mechanisms, and applications.